BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30545926)

  • 21. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
    Cervantes F; Ross DM; Radinoff A; Palandri F; Myasnikov A; Vannucchi AM; Zachee P; Gisslinger H; Komatsu N; Foltz L; Mannelli F; Passamonti F; Gilotti G; Sadek I; Tiwari R; Zor E; Al-Ali HK
    Leukemia; 2021 Dec; 35(12):3455-3465. PubMed ID: 34017073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
    Breccia M; Baratè C; Benevolo G; Bonifacio M; Elli EM; Guglielmelli P; Maffioli M; Malato A; Mendicino F; Palumbo GA; Pugliese N; Rossi E; Rumi E; Sant'Antonio E; Ricco A; Tiribelli M; Palandri F
    Ann Hematol; 2020 Jan; 99(1):65-72. PubMed ID: 31832751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
    Bose P; Swaminathan M; Pemmaraju N; Ferrajoli A; Jabbour EJ; Daver NG; DiNardo CD; Alvarado Y; Yilmaz M; Huynh-Lu J; Qiao W; Wang X; Matamoros A; Zhou L; Pierce S; Schroeder KD; Kantarjian HM; Verstovsek S
    Leuk Lymphoma; 2019 Jul; 60(7):1767-1774. PubMed ID: 30632841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose ruxolitinib shows effective in treating myelofibrosis.
    Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
    Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
    Stein BL; Swords R; Hochhaus A; Giles F
    Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
    Kong T; Laranjeira ABA; Collins TB; De Togni ES; Wong AJ; Fulbright MC; Ruzinova M; Celik H; Challen GA; Fisher DAC; Oh ST
    Blood Adv; 2022 Jan; 6(2):611-623. PubMed ID: 34644371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
    Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.
    Isberner N; Kraus S; Grigoleit GU; Aghai F; Kurlbaum M; Zimmermann S; Klinker H; Scherf-Clavel O
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):973-983. PubMed ID: 34505930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
    Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
    J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
    [No Abstract]   [Full Text] [Related]  

  • 38. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
    Tavallai M; Booth L; Roberts JL; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(14):17290-300. PubMed ID: 26981780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.